Cerveau has signed a research agreement through which it will supply its early-stage imaging agent to assess the stages of Alzheimer’s disease and other neurodegenerative diseases.
In an exclusive licensing agreement with Merck & Co Inc (MSD), Cerveau will take on development of the firm’s investigative PET imaging agent up to Phase III trials for Alzheimer’s Disease.
European organisations representing academic CROs and nuclear medicine researchers have established an accreditation programme for a novel Zirconium-PET imaging technique, used in early development of monoclonal antibodies.
Siemens has outlined plans to establish itself as a leading provider of radiopharmaceuticals in India through the construction of numerous manufacturing facilities.
Positron emission tomography (PET) imaging with the radiotracer
fluorodeoxyglucose (FDG) could be used to detect Alzheimer's
disease in patients who have mild cognitive impairment, according
to a study reported in the October...
A healthcare facility the US has been cleared by the Food and Drug
Administration to manufacture high-strength fludeoxyglucose F 18, a
drug used for diagnostic imaging with positron emission tomography
(PET).
The US Food and Drug Administration (FDA) has drafted a current
Good Manufacturing Practice (cGMP) regulation for the production of
drugs used in positron emission tomography (PET), a diagnostic
tool.
The use of positron emission tomography (PET) and small animal
imaging has the potential to eliminate more strenuous drug
development trials with animals, creating a viable alternative.